LncRNA LINC01315 silencing modulates cancer stem cell properties and epithelial-to-mesenchymal transition in colorectal cancer via miR-484/DLK1 axis

Li, Youran; Wang, Wei; Wu, Minna; Zhu, Ping; Zhou, Zailong; Gong, Yuxia; Gu, Yunfei

doi:10.1080/15384101.2022.2033415

Cited by 8 publications

(7 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-484 constitutes a tumor-suppressor miRNA and plays a role in the epithelial-to-mesenchymal transition (EMT) by targeting the DLK1 gene. [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer

Gherman

Bălăcescu

Popa

et al. 2023

IJMS

View full text Add to dashboard Cite

The status of predictive biomarkers in metastatic colorectal cancer is currently underdeveloped. Our study aimed to investigate the predictive value of six circulating exosomal miRNAs derived from plasma (miR-92a-3p, miR-143-3p, miR-146a-5p, miR-221-3p, miR-484, and miR-486-5p) for chemosensitivity, resistance patterns, and survival. Thirty-one metastatic colorectal cancer patients were selected before receiving first-line irinotecan- or oxaliplatin-based chemotherapy. Blood samples were harvested at baseline and 4–6 months after the initiation of chemotherapy. The levels of exosomal expression for each miRNA were analyzed by qPCR. Our results for patients receiving first-line FOLFOX showed significantly higher baseline levels of miR-92a-3p (p = 0.007 **), miR-146a-5p (p = 0.036 *), miR-221-3p (p = 0.047 *), and miR-484 (p = 0.009 **) in non-responders (NR) vs. responders (R). Of these, miR-92a-3p (AUC = 0.735), miR-221-3p (AUC = 0.774), and miR-484 (AUC = 0.725) demonstrated a predictive ability to discriminate responses from non-responses, regardless of the therapy used. Moreover, Cox regression analysis indicated that higher expression levels of miR-92a-3p (p = 0.008 **), miR-143-3p (p = 0.009 **), miR-221-3p (p = 0.016 *), and miR-486-5p (p = 0.019 *) at baseline were associated with worse overall survival, while patients expressing higher baseline miR-92a-3p (p = 0.003 **) and miR-486-5p (p = 0.003 **) had lower rates of progression-free survival. No predictive values for candidate microRNAs were found for the post-chemotherapy period. In line with these findings, we conclude that the increased baseline exosomal expression of miR-92a-3p and miR-221-3p seems to predict a lack of response to chemotherapy and lower OS. However, further prospective studies on more patients are needed before drawing practice-changing conclusions.

show abstract

“…MiR-484 constitutes a tumor-suppressor miRNA and plays a role in the epithelial-to-mesenchymal transition (EMT) by targeting the DLK1 gene. [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer

Gherman

Bălăcescu

Popa

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Zhang et al ( 2022a ) reported that RNASEH1-AS1 exacerbated its oncogenicity of NSCLC through regulating miR-516a-5p/FOXK1 axis and facilitating Wnt/β-catenin signaling pathway activation. Li et al ( 2022b ) found that downregulation of LINC01315 modulated the properties of cancer stem cells and EMT of colorectal cancer through miR-484/DLK1 axis. Furthermore, Chi et al ( 2018 ) reported that RP11-79H23.3 could promote bladder cancer progression through sponging miR-107.…”

Section: Discussionmentioning

confidence: 99%

RP11-79H23.3 Inhibits the Proliferation and Metastasis of Non-small-cell Lung Cancer Through Promoting miR-29c

Liu

et al. 2022

Biochem Genet

View full text Add to dashboard Cite

Evidences indicate that long non-coding RNAs (lncRNAs) are closely involved and contributed to tumorigenesis and cancer progression. As a novel lncRNA, RP11-79H23.3 was found to be an anti-oncogene in bladder cancer. However, the essential roles and functions of RP11-79H23.3 in non-small-cell lung cancer (NSCLC) remains to be elucidated. Here, loss of functional assay was applied to gain insights into the functions of RP11-79H23.3 on the proliferation and metastasis capabilities of A549 and H1299 cells. Meantime, Real-time PCR was utilized to measure RP11-79H23.3 and miR-29c expression in NSCLC tissues. Dual-luciferase reporter assay, CCK8, colony formation assay, transwell and Western blot were performed to illustrate the potential molecular basis of RP11-79H23.3 in NSCLC. RP11-79H23.3 downregulation facilitated cell proliferation, migration, and invasion of NSCLC. The result of dual-luciferase reporter assay represented a direct interaction of RP11-79H23.3 with miR-29c, which suppressed miR-29c expression that showed inversely correlation in NSCLC. Moreover, RP11-79H23.3 siRNA facilitated the progression of NSCLC partially via regulating the expression of miR-29c and the activation of Wnt/β-catenin signaling pathway. Our findings highlighted that RP11-79H23.3, served as an anti-oncogene, accelerated NSCLC progression through sequestering miR-29c, providing a promising therapeutic target for NSCLC.

show abstract

“…Patients treated with capecitabine (CAPE) for stage IV CRC that exhibited low levels of miR-143 expression in the primary tumors had improved progression-free survival (PFS) [ 34 ]. miR-484 is a tumor suppressor in CRC, and high levels of expression in the plasma of patients with mCRC, together with low levels of miR-106a and miR-130b, were associated with a lack of response to chemotherapy in the study conducted by Li et al [ 35 ]. Other research teams found an association between a low tissue expression level of miR-31-3p and a better response to anti-EGFR monoclonal antibodies [ 36 ].…”

Section: The Role Of Micrornas In the Diagnosis Prognosis And Predict...mentioning

confidence: 99%

Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

Gherman,

Bolundut,

Ecea

et al. 2024

Medicina

View full text Add to dashboard Cite

Currently, only a limited set of molecular traits are utilized to direct treatment for metastatic CRC (mCRC). The molecular classification of CRC depicts tumor heterogeneity based on gene expression patterns and aids in comprehending the biological characteristics of tumor formation, growth and prognosis. Additionally, it assists physicians in tailoring the therapeutic approach. Microsatellite instability (MSI-H)/deficient mismatch repair proteins (MMRd) status has become a ubiquitous biomarker in solid tumors, caused by mutations or methylation of genes and, in turn, the accumulation of mutations and antigens that subsequently induce an immune response. Immune checkpoint inhibitors (ICI) have recently received approval for the treatment of mCRC with MSI-H/MMRd status. However, certain individuals experience either initial or acquired resistance. The tumor-programmed cell death ligand 1 (PD-L1) has been linked to the ability of CRC to evade the immune system and promote its growth. Through comprehensive research conducted via the PUBMED database, the objectives of this paper were to review the molecular characteristics linked to tumor response in metastatic CRC in light of improved patients’ outcomes following ICI therapies as seen in clinical trials and to identify particular microRNAs that can modulate the expression of specific oncoproteins, such as PD-L1, and disrupt the mechanisms that allow the immune system to be evaded.

show abstract

LncRNA LINC01315 silencing modulates cancer stem cell properties and epithelial-to-mesenchymal transition in colorectal cancer via miR-484/DLK1 axis

Cited by 8 publications

References 62 publications

Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer

Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer

RP11-79H23.3 Inhibits the Proliferation and Metastasis of Non-small-cell Lung Cancer Through Promoting miR-29c

Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

Contact Info

Product

Resources

About